Indeed, Nanou et al.[17] (2020) encouraged the screening of vesicular HER2 in clinical settings as they found blood circulating EVs extremely informative on the presence of HER2-positive primary tumors and proposed them as valuable prognostic factors complementing circulating tumor cells (CTCs)[17]. This evidence concerns the gene ERBB2 and neoplasm.